Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma — Stella

Recruiting

Back to Kidney Cancer trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai

Key details

Phase

Safety & dosing

Sponsor

Fudan University

Enrollment target

~66 participants

Started

January 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated January 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov